TAIPEI, Taiwan, April 21, 2025 — AP Biosciences, a biopharmaceutical firm in its clinical stage focused on revolutionizing cancer treatment through cutting-edge bispecific antibodies, has announced it will share preclinical findings in a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL, from April 25-30, 2025.

The data will highlight the potential of AP402, a novel T cell engager targeting CD137 and p95HER2 in both in-vivo and in vitro studies. AP402 was recently approved for clinical trials in Australia this past February.

Poster presentation details:

Title: AP402, a bispecific antibody targets p95HER2 and CD137, shows a potent antitumor activity
Poster Number: 6016
Presenter: Dr. Po-Lin Huang, Associate Director, Antibody Discovery
Session: Clinical Research, Therapeutic Antibodies, Including Engineered Antibodies 2
Location: Poster Section 35
Date and Time: 4/29/2025 2:00 – 5:00 PM

The poster will be accessible on the AP Bioscience website after the session.

About AP402

AP402, created and developed by AP Biosciences, is a first-in-class bispecific antibody designed to target p95HER2, a HER2 variant found in 30-40% of HER2-positive cancers resistant to treatment. AP402 combines p95HER2 binding with a CD137 activation domain, enabling targeted T-cell activation within the tumor microenvironment. This design promotes HER2 variant clustering to effectively initiate CD137-mediated T-cell activation, reducing the risk of systemic cytokine release-related toxicity. The p95HER2 and CD137 binding domains are engineered to improve the connection between HER2 variant-expressing cancer cells and CD137-expressing T-cells, ensuring efficient immune cell recruitment. This innovative mechanism positions AP402 as a promising therapy for tumors resistant to traditional anti-HER2 treatments, potentially offering new hope for patients with refractory/recurrent cancers.

About AP Biosciences

AP Biosciences, based in Taiwan, is a clinical-stage biopharmaceutical company focused on creating innovative antibody-based treatments for cancer and other diseases. Utilizing its proprietary Omni-Mab and T-cube platforms, AP Biosciences is developing next-generation bispecific antibodies that precisely activate the immune system for both established and treatment-resistant cancers.

AP Biosciences Contact
Spike Lo
AP Biosciences

+886-2-2653-2886

Media Contact
Jason Braco, PhD
LifeSci Communications
(908)-432-4243